Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 3,553 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluids Clear all

Conditions: HIV Infections, Human Immunodeficiency Virus
Interventions: SP01A; Drug
Lead sponsor: Samaritan Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 5
States / cities: Beverly Hills, California • Fort Lauderdale, Florida • Orlando, Florida + 2 more

Conditions: Ovarian Cancer
Interventions: Nutritional Counseling, Daily Supplements; Behavioral · Dietary Supplement
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Esophageal Cancer
Interventions: General Electric LOGIQ E9 ultrasound system; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy Volunteers
Interventions: Febuxostat XR, Maalox Advance Regular Strength liquid; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hypothermia; Anesthesia, Hypothermia, Newborn, Hypothermia, Sequela
Interventions: Pre op upper body forced air warming (32˚C), Pre op lower body forced air warming (32˚C), Pre op fluids (45˚C), Intra op upper body forced air warming (32˚C), Intra op fluids at room temperature, Intra op upper body forced air warming at (32˚C), Intra op upper body forced air warming at (42˚C), Intra op lower body forced air warming at (32˚C), Intra op lower body forced air warming at (42˚C), Intra op fluid (42˚C); Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Prevention, Transgender Women
Interventions: Alternative long-acting PrEP injection strategies, mHealth adherence app; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: Oral nutrition supplement - control, Oral nutrition supplement - test; Other
Lead sponsor: Société des Produits Nestlé (SPN); Industry
Eligibility: 20 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Tustin, California

Conditions: AML, CML, MDS
Interventions: CYT107 - Recombinant glycosylated human interleukin 7., rhIL-7 (CYT107); Drug
Lead sponsor: Cytheris, Inc.; Industry
Eligibility: 15 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Glucose Transporter Type 1 Deficiency Syndrome, GLUT1 Deficiency Syndrome
Interventions: Triheptanoin; Drug
Lead sponsor: Juan Pascual; Other
Eligibility: 1 Month to 20 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cancer
Interventions: 1 tablet composed of antioxidants and minerals; Dietary Supplement
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Pulmonary TB
Interventions: ID93 + GLA-SE; Biological
Lead sponsor: Access to Advanced Health Institute (AAHI); Other
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy
Interventions: Tasso+™; Device
Lead sponsor: Alachua Government Services, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Riverside, California

Conditions: Amyotrophic Lateral Sclerosis, Neurodegenerative Disease, Motor Neuron Disease
Interventions: Not listed
Lead sponsor: Drexel University College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pancreatic Carcinoma, Pancreatic Neoplasm
Interventions: Biospecimen Collection, Distal Pancreatectomy, Lanreotide, Questionnaire Administration, Saline; Procedure · Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 118
States / cities: Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 93 more

Conditions: Human Metapneumovirus, Human Parainfluenza Virus Type 3
Interventions: B/HPIV3/HMPV-PreF-A vaccine, B/HPIV3/HMPV-F-B365 vaccine, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 24 Months to 59 Months
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Baltimore, Maryland • Columbia, Maryland • Rochester, New York + 1 more

Conditions: Respiratory Syncytial Virus
Interventions: mRNA-1345, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 0 Years to 40 Years
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 22
States / cities: Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 19 more

Conditions: Non-Insulin-Dependent Diabetes Mellitus
Interventions: pioglitazone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Severe Thermal Injury, Greater Than 20% TBSA
Interventions: Vitamin C, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Alzheimer Disease
Interventions: AC-OLE-01-VA; Drug
Lead sponsor: Cerecin; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Congestive Heart Failure(CHF)
Interventions: Kyma Device u-Cor System; Device
Lead sponsor: The Christ Hospital; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Patients Who Are in Shock and Intubated in the Trauma Bay (TB)
Interventions: Limited Transthoracic Echocardiogram (LTTE, SonoSite Ultrasound), Usual care; Device · Other
Lead sponsor: Riverside University Health System Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Moreno Valley, California

Conditions: Preterm Birth, Breast Milk Expression, Nutrition Disorder, Infant, Brain Development Abnormality, Neurodevelopmental Disorders
Interventions: Individually targeted fortification; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 1 Day to 21 Days
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Mineral Absorption
Interventions: Vitamin D; Dietary Supplement
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 4 Years to 8 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Same-day Discharge, Length of Stay
Interventions: Complex Carbohydrate Drink; Dietary Supplement
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 75 Years
Enrollment: 312 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients

Juice Plus+ and Juice Plus+ Complete in Ovarian Cancer

Use of Intra-Operative Shear Wave Ultrasound Vibrometry for Characterization of Esophageal Malignant Tumors

Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule

Perioperative Warming Measures in Cesarean Delivery

Long-acting Biomedical HIV Prevention in Transgender Women

Glucose Response in Persons with Type 2 Diabetes

Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant

Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D)

Study for the Liquid Chromatography-mass Spectrometry (LC-MS/MS) Assessment of Oxidative DNA Damage in Relation to Antioxidant Usage

Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults

Evaluating Technologies for Point-of-Care Blood Collections by Patients

Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers

Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylurea, Metformin And Insulin, Or Insulin

Vitamin C for Severe Thermal Injuries

A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin and Matching Placebo in Healthy Subjects

KYMA Device: External Measure of Thoracic Fluid and Vital Signs

The Prognostic Value of Limited Transthoracic Echocardiogram (LTTE) During Trauma Resuscitation

Targeting Human Milk Fortification to Improve Preterm Infant Growth and Brain Development

Evaluation of Calcium, Vitamin D, Magnesium, and Zinc Absorption in Children

Preoperative Oral Hydration in the Ambulatory Arthroplasty Population